DCMD
MCID: MCL027
MIFTS: 50

Macular Dystrophy, Dominant Cystoid (DCMD)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 56 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 58 71
Cystoid Macular Dystrophy 56 58
Macular Edema, Cystoid 56 71
Dcmd 56 58
Cystoid Macular Dystrophy; Cymd 56
Familial Macular Edema 58
Macular Retinal Edema 71
Macular Edema 43
Cymd 56
Mddc 56

Characteristics:

Orphanet epidemiological data:

58
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

56
Inheritance:
autosomal dominant (7p21-p15)


HPO:

31
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4447
OMIM 56 153880
MeSH 43 D008269
NCIt 49 C34794
SNOMED-CT 67 193387007
ICD10 via Orphanet 33 H35.5
Orphanet 58 ORPHA75381
MedGen 41 C0024440
UMLS 71 C0024440 C0271051 C0730317

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM : 56 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to vitreoretinopathy, neovascular inflammatory and uveitis, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy), and among its related pathways/superpathways is Visual Cycle in Retinal Rods. The drugs Acetazolamide and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are edema and strabismus

Related Diseases for Macular Dystrophy, Dominant Cystoid

Diseases related to Macular Dystrophy, Dominant Cystoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 vitreoretinopathy, neovascular inflammatory 32.8 VEGFA RPE65 CRYAA
2 uveitis 32.0 TNFRSF1B SERPINF1 CRYAA
3 microvascular complications of diabetes 1 31.6 VEGFA SERPINF1 PRKCB CXCL12
4 diabetic macular edema 31.6 VEGFA SERPINF1 PRKCB
5 retinal vein occlusion 31.5 VEGFA SERPINF1 CXCL12 ACE
6 retinal ischemia 31.4 VEGFA CXCL12 CRYAA
7 retinal detachment 31.4 VEGFA SERPINF1 RS1 CXCL12
8 vitreous detachment 31.3 VEGFA KCNMA1
9 vitreoretinochoroidopathy 31.3 RPE65 PRPH2 BEST1 ABCA4
10 bestrophinopathy, autosomal recessive 31.3 RPE65 PRPH2 CRB1 BEST1 ABCA4
11 branch retinal artery occlusion 31.0 VEGFA CRYAA
12 intraocular pressure quantitative trait locus 30.9 VEGFA SERPINF1 PEX19 CRYAA
13 severe nonproliferative diabetic retinopathy 30.9 VEGFA PRKCB ACE
14 panuveitis 30.8 TNFRSF1B MRAP ACE
15 exudative vitreoretinopathy 1 30.8 VEGFA SERPINF1 CRYAA
16 optic disk drusen 30.8 KCNMA1 CRB1
17 iritis 30.8 TNFRSF1B MRAP ACE
18 retinal vascular disease 30.8 VEGFA SERPINF1 CRYAA ACE
19 neuroretinitis 30.8 RCVRN MRAP ACE
20 iridocyclitis 30.7 VEGFA TNFRSF1B MRAP ACE
21 endophthalmitis 30.7 VEGFA RPE65 MRAP CRYAA
22 cancer-associated retinopathy 30.7 VEGFA RCVRN
23 diabetic cataract 30.7 VEGFA SERPINF1 CRYAA
24 exanthem 30.6 VEGFA TNFRSF1B ACE
25 eales disease 30.6 VEGFA SERPINF1
26 retinal artery occlusion 30.6 VEGFA CRYAA ACE
27 glaucoma, primary open angle 30.6 PEX19 CRYAA ABCA4
28 toxic maculopathy 30.6 NR2E3 ABCA4
29 ocular tuberculosis 30.6 MRAP ACE
30 posterior scleritis 30.6 MRAP ACE
31 retinal vasculitis 30.6 TNFRSF1B MRAP ACE
32 nonsyndromic retinitis pigmentosa 30.5 USH2A ABCA4
33 keratitis, hereditary 30.5 VEGFA CRYAA BEST1
34 neovascular glaucoma 30.5 VEGFA RS1 PEX19 CRYAA
35 retinal vascular occlusion 30.4 VEGFA SERPINF1 KCNMA1 CRYAA
36 coats disease 30.4 VEGFA RS1 CRB1
37 hypertensive retinopathy 30.4 VEGFA ACE
38 optic papillitis 30.2 TNFRSF1B MRAP ACE
39 diabetic neuropathy 30.2 VEGFA PRKCB ACE
40 gyrate atrophy of choroid and retina 30.1 RPE65 PRPH2 ABCA4
41 chorioretinitis 30.1 VEGFA TNFRSF1B MRAP CRB1 ACE
42 leukocoria 30.1 RS1 CRYAA
43 nanophthalmos 30.0 RPE65 CRB1 BEST1
44 impotence 29.9 VEGFA KCNMA1 ACE
45 pseudopapilledema 29.9 RPE65 CRB1
46 vitreoretinal dystrophy 29.9 RS1 NR2E3 CRYAA
47 exudative vitreoretinopathy 29.8 VEGFA NR2E3 ABCA4
48 microvascular complications of diabetes 5 29.7 VEGFA SERPINF1 PRKCB CXCL12 CRYAA ACE
49 yemenite deaf-blind hypopigmentation syndrome 29.7 VEGFA USH2A RPE65 CRB1 ABCA4
50 choroiditis 29.7 VEGFA TNFRSF1B MRAP ACE ABCA4

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 edema 31 HP:0000969
2 strabismus 31 HP:0000486
3 hypermetropia 31 HP:0000540
4 macular dystrophy 31 HP:0007754
5 cystoid macular edema 31 HP:0011505
6 pericentral retinitis pigmentosa 31 HP:0007947

Symptoms via clinical synopsis from OMIM:

56
Eyes:
strabismus
cystoid macular edema
pericentral retinitis pigmentosa
whitish punctate vitreous deposits
moderate to high hyperopia
more
Radiology:
normal electroretinogram

Clinical features from OMIM:

153880

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Dystrophy, Dominant Cystoid:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.97 ABCA4 CRB1 CXCL12 KCNMA1 NR2E3 PRKCB
2 cardiovascular system MP:0005385 9.96 ABCA4 ACE CRB1 CXCL12 KCNMA1 PRKCB
3 pigmentation MP:0001186 9.5 ABCA4 BEST1 CRB1 PRPH2 RPE65 RS1
4 vision/eye MP:0005391 9.4 ABCA4 BEST1 CRB1 NR2E3 PRPH2 RCVRN

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Bevacizumab Approved, Investigational Phase 4 216974-75-3
6
Bromfenac Approved Phase 4 91714-94-2 60726
7
Homatropine Approved Phase 4 87-00-3
8
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
9
Iodine Approved, Investigational Phase 4 7553-56-2 807
10
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Povidone-iodine Approved Phase 4 25655-41-8
13
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
14
Povidone Approved Phase 4 9003-39-8
15
Travoprost Approved Phase 4 157283-68-6 5282226
16
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
17
Interferon beta-1b Approved Phase 4 145155-23-3
18
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
21
Verteporfin Approved, Investigational Phase 4 129497-78-5
22
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
23
Ofloxacin Approved Phase 4 82419-36-1 4583
24
Difluprednate Approved Phase 4 23674-86-4 443936
25
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
26
Phenylephrine Approved Phase 4 59-42-7 6041
27
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
28
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
29
Fenofibrate Approved Phase 4 49562-28-9 3339
30
Dipivefrin Approved Phase 4 52365-63-6 3105
31
Simvastatin Approved Phase 4 79902-63-9 54454
32
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
36 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
leucovorin Approved Phase 4 58-05-9 6006 143
39
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
40
Empagliflozin Approved Phase 4 864070-44-0
41
Glimepiride Approved Phase 4 93479-97-1 3476
42
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
46
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
47 Anticonvulsants Phase 4
48 diuretics Phase 4
49 Cardiac Glycosides Phase 4
50 Glycoside Hydrolase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 936)
# Name Status NCT ID Phase Drugs
1 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
2 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
3 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
4 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
5 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
6 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
7 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
8 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
9 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
10 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
11 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
12 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
13 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
14 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
15 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
16 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
17 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
18 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
19 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
20 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
21 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
22 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
23 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
24 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
25 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
26 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
27 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
28 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac
29 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
30 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
31 The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery Completed NCT02646072 Phase 4 Ketorolac tromethamine ophthalmic solution 0.45%
32 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
33 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
34 Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
35 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
36 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
37 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
38 Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification Completed NCT01385852 Phase 4
39 Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial Completed NCT03383328 Phase 4 NSAID + prednisolone, preoperative;NSAID + prednisolone, postoperative;NSAID, preoperative;NSAID, postoperative;Drop-less surgery
40 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
41 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery Completed NCT02819908 Phase 4 Imprimis Dropless;Imprimis Less Drops
42 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
43 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
44 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
45 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
46 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
47 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
48 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
49 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
50 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Flurbiprofen
Flurbiprofen sodium

Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

40
Eye, Endothelial, Retina, Testes, Bone, Brain, Liver

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 183)
# Title Authors PMID Year
1
Dominant cystoid macular dystrophy. 61 56
25267528 2015
2
Localization of the gene for dominant cystoid macular dystrophy on chromosome 7p. 56 61
8004098 1994
3
Retinal functions in dominant cystoid macular dystrophy (DCMD). 61 56
990013 1976
4
Loci for autosomal dominant retinitis pigmentosa and dominant cystoid macular dystrophy on chromosome 7p are not allelic. 56
8079997 1994
5
Dominantly inherited cystoid macular edema. 56
420475 1979
6
Dominant cystoid macular dystrophy. 56
836665 1977
7
Dominantly inherited cystoid macular edema. 56
970419 1976
8
Dye synthetic solution treatment by direct contact membrane distillation using commercial membranes. 61
30569840 2020
9
Macrovoid-Inhibited PVDF Hollow Fiber Membranes via Spinning Process Delay for Direct Contact Membrane Distillation. 61
32469495 2020
10
Direct contact membrane distillation for effective concentration of perfluoroalkyl substances - Impact of surface fouling and material stability. 61
32544734 2020
11
Energy efficiency of membrane distillation: Simplified analysis, heat recovery, and the use of waste-heat. 61
32126386 2020
12
Recovery of dissolved methane from anaerobically treated food waste leachate using solvent-based membrane contactor. 61
32203817 2020
13
Macro-corrugated and nano-patterned hierarchically structured superomniphobic membrane for treatment of low surface tension oily wastewater by membrane distillation. 61
32088385 2020
14
Proof-of-Concept for Gas-Entrapping Membranes Derived from Water-Loving SiO2/Si/SiO2 Wafers for Green Desalination. 61
32176215 2020
15
Enhancement of Flux Performance in PTFE Membranes for Direct Contact Membrane Distillation. 61
32033433 2020
16
Electrochemical Oxidation-Membrane Distillation Hybrid Process: Utilizing Electric Resistance Heating for Distillation and Membrane Defouling through Thermal Activation of Anodically Formed Persulfate. 61
31934752 2020
17
Developing and validating a dynamic model of water production by direct-contact membrane distillation. 61
32208423 2020
18
Mechanism of biofilm formation on a hydrophobic polytetrafluoroethylene membrane during the purification of surface water using direct contact membrane distillation (DCMD), with especial interest in the feed properties. 61
31928216 2020
19
Analysis of mass transfer behavior in membrane distillation: Mathematical modeling under various conditions. 61
31306977 2019
20
Membrane distillation as post-treatment for anaerobic fluidized bed membrane bioreactor for organic and nitrogen removal. 61
31238271 2019
21
One-step tailoring surface roughness and surface chemistry to prepare superhydrophobic polyvinylidene fluoride (PVDF) membranes for enhanced membrane distillation performances. 61
31200232 2019
22
Combined Osmotic and Membrane Distillation for Concentration of Anthocyanin from Muscadine Pomace. 61
31313316 2019
23
Application of direct contact membrane distillation for saline dairy effluent treatment: performance and fouling analysis. 61
29948689 2019
24
Slippery for scaling resistance in membrane distillation: A novel porous micropillared superhydrophobic surface. 61
30844676 2019
25
Triple-Layer Nanofiber Membranes for Treating High Salinity Brines Using Direct Contact Membrane Distillation. 61
31064093 2019
26
Performance Comparison between Polyvinylidene Fluoride and Polytetrafluoroethylene Hollow Fiber Membranes for Direct Contact Membrane Distillation. 61
30978973 2019
27
Effective treatment of reverse osmosis concentrate from incineration leachate using direct contact membrane distillation coupled with a NaOH/PAM pre-treatment process. 61
30583212 2019
28
Optimization of membrane modification using SiO2 for robust anti-fouling performance with calcium-humic acid feed in membrane distillation. 61
30623884 2019
29
Influence of Hydraulic Pressure on Performance Deterioration of Direct Contact Membrane Distillation (DCMD) Process. 61
30845780 2019
30
Acid mine drainage treatment by integrated submerged membrane distillation-sorption system. 61
30609501 2019
31
Experimental Evaluation of the Thermal Polarization in Direct Contact Membrane Distillation Using Electrospun Nanofiber Membranes Doped With Molecular Probes. 61
30759729 2019
32
Surface Modification of PVDF Membranes for Treating Produced Waters by Direct Contact Membrane Distillation. 61
30813570 2019
33
Influence of dye class on the comparison of direct contact and vacuum membrane distillation applied to remediation of dyeing wastewater. 61
31361190 2019
34
Evaluating the potential of superhydrophobic nanoporous alumina membranes for direct contact membrane distillation. 61
30199828 2019
35
Fabrication of Janus Membranes for Desalination of Oil-Contaminated Saline Water. 61
30511847 2018
36
Three-dimensional shape and velocity changes affect responses of a locust visual interneuron to approaching objects. 61
30341087 2018
37
Fluorographite-co-polydimethylsiloxane coated polyvinylidene-fluoride membrane for desalination of highly saline water with humic acid in direct contact membrane distillation. 61
30075397 2018
38
Application of membrane distillation for the treatment of anaerobic membrane bioreactor effluent: An especial attention to the operating conditions. 61
29890491 2018
39
Stable Superhydrophobic Ceramic-Based Carbon Nanotube Composite Desalination Membranes. 61
30085681 2018
40
Performance evaluation of hybrid OMBR-MD using organic and inorganic draw solutions. 61
30252655 2018
41
Membrane distillation for industrial wastewater treatment: Studying the effects of membrane parameters on the wetting performance. 61
29803107 2018
42
Direct contact membrane distillation applied to saline wastewater: parameter optimization. 61
30065134 2018
43
Mixed Matrix Polytetrafluoroethylene/Polysulfone Electrospun Nanofibrous Membranes for Water Desalination by Membrane Distillation. 61
29924587 2018
44
Removal of selected pesticides from groundwater by membrane distillation. 61
28424956 2018
45
Fouling development in direct contact membrane distillation: Non-invasive monitoring and destructive analysis. 61
29304446 2018
46
Comparison of colloidal silica involved fouling behavior in three membrane distillation configurations using PTFE membrane. 61
29248804 2018
47
Performance and fouling mechanism of direct contact membrane distillation (DCMD) treating fermentation wastewater with high organic concentrations. 61
29548396 2018
48
Performance and Fouling Study of Asymmetric PVDF Membrane Applied in the Concentration of Organic Fertilizer by Direct Contact Membrane Distillation (DCMD). 61
29462942 2018
49
Modeling the Concentration of Volatile and Semivolatile Contaminants in Direct Contact Membrane Distillation (DCMD) Product Water. 61
29111695 2017
50
Direct contact membrane distillation for textile wastewater treatment: a state of the art review. 61
29168697 2017

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EYS NM_001142800.2(EYS):c.8519A>G (p.Glu2840Gly)SNV Uncertain significance 523415 rs1554163965 6:64431408-64431408 6:63721512-63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

Pathways related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 RPE65 RCVRN PRKCB

GO Terms for Macular Dystrophy, Dominant Cystoid

Cellular components related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 9.13 RCVRN PRPH2 ABCA4
2 photoreceptor inner segment GO:0001917 9.02 USH2A RS1 RCVRN PRPH2 CRB1

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.61 USH2A RS1 RPE65 RCVRN PRPH2 NR2E3
2 photoreceptor cell maintenance GO:0045494 9.58 USH2A CRB1 ABCA4
3 retina development in camera-type eye GO:0060041 9.55 SERPINF1 RPE65 PRPH2 NR2E3 CRB1
4 regulation of calcium ion transport GO:0051924 9.54 RCVRN CXCL12 BEST1
5 detection of light stimulus involved in visual perception GO:0050908 9.5 RPE65 CRB1 BEST1
6 induction of positive chemotaxis GO:0050930 9.49 VEGFA CXCL12
7 retina morphogenesis in camera-type eye GO:0060042 9.48 RPE65 CRB1
8 positive regulation of axon extension involved in axon guidance GO:0048842 9.46 VEGFA CXCL12
9 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.43 VEGFA ACE
10 eye photoreceptor cell development GO:0042462 9.43 VEGFA NR2E3 CRB1
11 visual perception GO:0007601 9.32 USH2A RS1 RPE65 RCVRN PRPH2 NR2E3

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....